1006717-20-9

Basic information

• Product Name: 1-(1,4-Benzodioxan-2-ylcarbonyl)piperazine-D8
• Synonyms: 1-(1,4-Benzodioxan-2-ylcarbonyl)piperazine-D8; 1-[(2,3-Dihydro-1,4-benzodioxin-2-yl)carbonyl]-piperazine-d8;(2,3-Dihydro-1,4-benzodioxin-2-yl)-1-piperazinyl-d8-methanone;((2,3-Dihydro-1,4-benzodioxin-2-yl)-1-piperazinyl-D8)
• CAS NO: 1006717-20-9
• Molecular Formula: C13H16N2O3
• Molecular Weight: 248.27774
• Product Categories: Heterocyclic Compounds;Heterocycles;Isotope Labeled Compounds;Aromatics;Isotope Labelled Compounds
• Mol File: 1006717-20-9.mol
• Article Data: 1

Chemical Properties

• Appearance: /
• Solubility: Dichloroform, Ethyl Acetate
• CAS DataBase Reference: 1-(1,4-Benzodioxan-2-ylcarbonyl)piperazine-D8(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(1,4-Benzodioxan-2-ylcarbonyl)piperazine-D8(1006717-20-9)
• EPA Substance Registry System: 1-(1,4-Benzodioxan-2-ylcarbonyl)piperazine-D8(1006717-20-9)

Safety Data

• Hazardous Substances Data: 1006717-20-9(Hazardous Substances Data)

Usage

Chemical Properties

Yellow Solid

Uses

A labelled intermediate of Doxazosin.

Relevant articles and documents

PREPARATION AND UTILITY OF SUBSTITUTED QUINAZOLINE COMPOUNDS WITH ALPHA-ADRENERGIC BLOCKING EFFECTS

The present disclosure is directed to modulators of alpha-adrenergic receptors and pharmaceutically acceptable salts and prodrugs thereof, the chemical synthesis thereof, and the use of such compounds for the treatment and/or management of hypertension, cardiac failure, prostatitis, and benign prostatic hyperplasia, and any other condition in which it is beneficial to modulate an alpha-adrenergic receptor.